New agents for intrathecal administration

Stacie Stapleton, Susan Blaney

Research output: Contribution to journalReview articlepeer-review

Abstract

Intrathecal administration of chemotherapy, with or without radiation therapy, is the primary treatment modality for the prevention and treatment of central nervous system (CNS) metastases in patients with leukemia or lymphoma. Although this treatment strategy has been very effective for patients with hematological malignancies, currently available intrathecal agents are relatively ineffective for patients with neoplastic meningitis resulting from an underlying solid or CNS tumor effective. This article provides an overview of some of the practical considerations and limitations associated with intrathecal chemotherapy, and is followed by a comprehensive review of some of the preclinical and early phase clinical trials of novel anticancer agents and treatment strategies using the intrathecal route.

Original languageEnglish (US)
Pages (from-to)528-534
Number of pages7
JournalCancer Investigation
Volume24
Issue number5
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

Keywords

  • Gemcitabine
  • Intrathecal
  • Mafosfamide
  • Neoplastic meningitis
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New agents for intrathecal administration'. Together they form a unique fingerprint.

Cite this